全文获取类型
收费全文 | 146313篇 |
免费 | 10550篇 |
国内免费 | 4190篇 |
专业分类
耳鼻咽喉 | 2026篇 |
儿科学 | 2876篇 |
妇产科学 | 2130篇 |
基础医学 | 7667篇 |
口腔科学 | 3330篇 |
临床医学 | 16409篇 |
内科学 | 20382篇 |
皮肤病学 | 2432篇 |
神经病学 | 7219篇 |
特种医学 | 4426篇 |
外国民族医学 | 39篇 |
外科学 | 22101篇 |
综合类 | 20658篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 6073篇 |
眼科学 | 2225篇 |
药学 | 11242篇 |
83篇 | |
中国医学 | 11142篇 |
肿瘤学 | 18568篇 |
出版年
2024年 | 341篇 |
2023年 | 2591篇 |
2022年 | 4753篇 |
2021年 | 6299篇 |
2020年 | 5853篇 |
2019年 | 5393篇 |
2018年 | 5144篇 |
2017年 | 5433篇 |
2016年 | 5785篇 |
2015年 | 5654篇 |
2014年 | 10303篇 |
2013年 | 12541篇 |
2012年 | 8653篇 |
2011年 | 9260篇 |
2010年 | 7817篇 |
2009年 | 7276篇 |
2008年 | 7021篇 |
2007年 | 7443篇 |
2006年 | 6593篇 |
2005年 | 5845篇 |
2004年 | 4758篇 |
2003年 | 4195篇 |
2002年 | 3483篇 |
2001年 | 3050篇 |
2000年 | 2476篇 |
1999年 | 1946篇 |
1998年 | 1600篇 |
1997年 | 1340篇 |
1996年 | 1153篇 |
1995年 | 994篇 |
1994年 | 793篇 |
1993年 | 608篇 |
1992年 | 527篇 |
1991年 | 497篇 |
1990年 | 423篇 |
1989年 | 360篇 |
1988年 | 349篇 |
1987年 | 301篇 |
1986年 | 256篇 |
1985年 | 309篇 |
1984年 | 285篇 |
1983年 | 205篇 |
1982年 | 208篇 |
1981年 | 193篇 |
1980年 | 165篇 |
1979年 | 164篇 |
1978年 | 111篇 |
1977年 | 56篇 |
1976年 | 75篇 |
1975年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献73.
74.
《The surgeon》2022,20(1):16-40
Surgical Innovations are central to surgical progress, and have led to exponential growth in various fields of Surgery. Surgical Innovations in Lower and Middle Income Countries are the result of creativity of frontline health workers in search of simple, safe and ethical solutions for their unique challenges. The key lies in: ‘simplifying the idea/technique/device’ to find patients' needs-driven low-cost innovative surgical solutions; which can be used on a wider scale to achieve health equity for underserved populations. Local surgeons understand the difficulties and nuances of various problems and can provide local-evidence-based customized solutions for their patients' health problems. We developed a Surgical Innovation Ecosystem allowing us to see difficulties as opportunities, learn from everyone and conduct research on what is ‘important’ rather than what is ‘interesting’. Barriers to Surgical Innovations in Lower and Middle Income Countries are well known; however, a roadmap to overcome these barriers is now available. The right balance has to be found between encouraging creativity and innovation while maintaining ethical awareness and responsibility to patients. Introduction and adoption of Surgical Innovations are governed by evidence-based principles and have to undergo a rigorous and scientific evaluation. Science of Surgical Innovations has finally come of age and is getting its due recognition and the pioneering innovators are receiving the much needed appreciation and support. 相似文献
75.
《Journal of the American College of Surgeons》2020,230(4):363-370
- Download : Download high-res image (207KB)
- Download : Download full-size image
76.
77.
中西医结合治疗动眼神经麻痹疗效观察 总被引:2,自引:0,他引:2
李春林 《中国实用神经疾病杂志》2015,(10)
目的了解中西医结合法治疗动眼神经麻痹的临床疗效。方法对我院2012-03—2014-03收治的动眼神经麻痹患者进行抽样,择取74例患者随机分成2组,对照组予以基础性西医疗法,实验组在对照组治疗基础上予以中医疗法(包括针刺及服用中药正容汤等),观察2组患者的临床治疗效果。结果实验组总有效率(94.60%)明显高于对照组(64.86%),差异具有统计学意义(P0.05)。结论中西医结合法治疗动眼神经麻痹临床疗效确切,安全系数高,值得临床大力推广使用。 相似文献
78.
《Urologic oncology》2015,33(5):217-225
Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation. 相似文献
79.
随着腔镜技术的进一步发展以及微创理念应用于结直肠外科疾病的诊治中,结直肠相关疾病的诊治发生了翻天覆地的变化。由传统的经腹手术到腹腔镜手术、经自然腔道手术,再到经自然腔道取标本手术(NOSES),结直肠疾病的外科诊治在微创领域取得了巨大成果。NOSES技术是目前结直肠外科在微创领域前沿的手术方式之一,它通过经直肠、阴道取标本来避免了腹壁的辅助取标本切口,从而将结直肠外科手术进一步微创化。NOSES技术集传统腹腔镜手术的优势与现代微创外科的理念于一体,它在确保手术效果的基础上集中体现了微创、加速康复外科、功能外科、"无疤"等理念的特点。本文主要就国内外各中心开展NOSES技术在结直肠外科诊治开展中的相关经验、心得和体会进行综述。 相似文献